BTK
Os inibidores da tirosina quinase de Bruton (BTK) são compostos que especificamente têm como alvo e inibem a BTK, uma enzima crucial envolvida na sinalização do receptor de células B e na regulação da angiogênese. A BTK desempenha um papel significativo na proliferação e sobrevivência de células cancerígenas, particularmente em malignidades hematológicas. Ao inibir a BTK, esses compostos podem interromper a angiogênese e o crescimento tumoral, tornando-os valiosos na terapia do câncer. Na CymitQuimica, oferecemos uma gama de inibidores de BTK de alta qualidade para apoiar sua pesquisa em oncologia, imunologia e angiogênese.
Foram encontrados 168 produtos para "BTK".
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
IBT6A hydrochloride
CAS:IBT6A hydrochloride: Ibrutinib impurity, Btk inhibitor IC50: 0.5 nM, used in dimer/adduct synthesis.Fórmula:C22H23ClN6OCor e Forma:SolidPeso molecular:422.91NX-5948
CAS:NX-5948 (BTK-IN-24) is a PROTAC-type BTK degrader with anti-inflammatory and anticancer activities, inhibiting B cell activation.Fórmula:C42H54N12O5Pureza:98.29%Cor e Forma:Yellow SolidPeso molecular:806.96Ref: TM-T75124
1mg80,00€5mg145,00€1mL*10mM (DMSO)178,00€10mg212,00€25mg339,00€50mg510,00€100mg708,00€Zanubrutinib-D5
Zanubrutinib-d5 (BGB-3111-d5) is a deuterium-labeled Zanubrutinib, an orally available Bruton's tyrosine kinase inhibitor for the study of B-cell malignancies.Fórmula:C27H29N5O3Pureza:>99.99%Cor e Forma:White SolidPeso molecular:476.58Elsubrutinib
CAS:Elsubrutinib (ABBV-105) is an orally active, selective, and irreversible BTK inhibitor with an IC50 of 0.18 μM for the catalytic domain of BTK.Fórmula:C17H19N3O2Pureza:99.77%Cor e Forma:White SolidPeso molecular:297.36Ref: TM-T39130
1mg145,00€5mg250,00€1mL*10mM (DMSO)268,00€10mg340,00€25mg573,00€50mg879,00€100mg1.314,00€Anti-BTK Antibody (3G585)
Anti-BTK Antibody (3G585) is an antibody targeting BTK. Anti-BTK Antibody (3G585) can be used in ELISA, IHC.Cor e Forma:Odour LiquidSpebrutinib
CAS:Spebrutinib (LMK-435) is an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplasticFórmula:C22H22FN5O3Pureza:97.02% - >99.99%Cor e Forma:SolidPeso molecular:423.44Olmutinib
CAS:Olmutinib is an oral mutant-specific EGFR inhibitor for cancer treatment with potential lower toxicity.Fórmula:C26H26N6O2SPureza:99.14% - 99.63%Cor e Forma:SolidPeso molecular:486.59Ref: TM-T6918
2mg37,00€5mg54,00€1mL*10mM (DMSO)56,00€10mg84,00€25mg130,00€50mg170,00€100mg268,00€200mg437,00€Acalabrutinib
CAS:Acalabrutinib (ACP-196), also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity.Fórmula:C26H23N7O2Pureza:98.94% - 99.64%Cor e Forma:White SolidPeso molecular:465.51Ref: TM-T3626
5mg44,00€1mL*10mM (DMSO)48,00€10mg57,00€25mg78,00€50mg90,00€100mg144,00€200mg215,00€500mg355,00€zanubrutinib
CAS:Zanubrutinib (BGB-3111) is an inhibitor of Bruton tyrosine kinase (BTK).Fórmula:C27H29N5O3Pureza:98.42% - 99.76%Cor e Forma:SolidPeso molecular:471.55Ref: TM-T7584
1mg52,00€2mg80,00€5mg124,00€1mL*10mM (DMSO)129,00€10mg215,00€25mg409,00€50mg612,00€100mg842,00€BMS-986142
CAS:BMS-986142 is a potent and highly selective reversible BTK inhibitor (IC50: 0.5 nM).Fórmula:C32H30F2N4O4Pureza:99.44% - 99.76%Cor e Forma:White SolidPeso molecular:572.6Ref: TM-T5138
1mg105,00€2mg165,00€5mg289,00€1mL*10mM (DMSO)358,00€10mg447,00€25mg715,00€50mg964,00€100mg1.243,00€200mg1.693,00€(Z)-LFM-A13
CAS:(Z)-LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK.Fórmula:C11H8Br2N2O2Pureza:99.88%Cor e Forma:SolidPeso molecular:360CHMFL-BMX-078
CAS:CHMFL-BMX-078 is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM.Fórmula:C33H35N7O6Pureza:>99.99%Cor e Forma:SolidPeso molecular:625.67BTK IN-1
CAS:BTK IN-1 (SNS062 analog) (SNS062 analog) is an effective BTK inhibitor (IC50: <100 nM).Fórmula:C19H21ClN6OPureza:97.38%Cor e Forma:SolidPeso molecular:384.86Ref: TM-TQ0230
1mg35,00€2mg50,00€5mg75,00€1mL*10mM (DMSO)84,00€10mg105,00€25mg170,00€50mg295,00€100mg416,00€Tolebrutinib
CAS:Tolebrutinib is an oral, selective BTK inhibitor, effective for MS research, with brain penetration and IC50s of 0.4/0.7 nM in cells.Fórmula:C26H25N5O3Pureza:98.4% - 98.82%Cor e Forma:SolidPeso molecular:455.51Ref: TM-T9125
2mg40,00€5mg71,00€1mL*10mM (DMSO)80,00€10mg105,00€25mg177,00€50mg264,00€100mg434,00€200mg622,00€Ibrutinib deacryloylpiperidine
CAS:Ibrutinib deacryloylpiperidine (IBT4A) is a highly selective Bruton’s tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM.Fórmula:C17H13N5OPureza:99.47%Cor e Forma:SolidPeso molecular:303.32Larotinib mesylate hydrate
CAS:Larotinib mesylate hydrate is a potent, broad-spectrum, and orally active tyrosine kinase inhibitor (TKI), primarily targeting EGFR with an IC50 value of 0.6 nMFórmula:C26H36ClFN4O11S2Cor e Forma:SolidPeso molecular:699.17Fenebrutinib
CAS:Fenebrutinib (GDC-0853) is a selective and noncovalent Btk inhibitor (Ki: 0.91 nM).Fórmula:C37H44N8O4Pureza:98.26% - 98.94%Cor e Forma:SolidPeso molecular:664.8(S)-Sunvozertinib
CAS:(S)-Sunvozertinib (DZD9008) is a rationally designed selective, irreversible EGFR/HER2 inhibitor.Fórmula:C29H35ClFN7O3Pureza:99.64%Cor e Forma:SolidPeso molecular:584.08N-piperidine Ibrutinib
CAS:N-piperidine Ibrutinib is a potent BTK inhibitor with IC50s of 51.0 for WT BTK and 30.7 nM for C481S BTK respectively.Fórmula:C22H22N6OPureza:96.65%Cor e Forma:SolidPeso molecular:386.45Remibrutinib
CAS:Remibrutinib inhibits BTK activity with an IC50 value of 0.023 μM in blood.Fórmula:C27H27F2N5O3Pureza:99.5% - 99.81%Cor e Forma:White SolidPeso molecular:507.53Ref: TM-T16730
1mg92,00€5mg210,00€1mL*10mM (DMSO)235,00€10mg340,00€25mg572,00€50mg713,00€100mg1.099,00€200mg1.485,00€PCI 29732
CAS:PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay.Fórmula:C22H21N5OPureza:99.81%Cor e Forma:SolidPeso molecular:371.43Tuxobertinib
CAS:Tuxobertinib (BDTX-189) is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations. BDTX-189 exhibits anticancer activity.Fórmula:C29H29ClN6O4Pureza:99.22%Cor e Forma:SolidPeso molecular:561.03Ref: TM-T9072
2mg38,00€5mg57,00€1mL*10mM (DMSO)71,00€10mg90,00€25mg178,00€50mg334,00€100mg497,00€200mg712,00€CNX-774
CAS:CNX-774 is a highly specific, irreversible, and orally active BTK inhibitor (IC50<1 nM).Fórmula:C26H22FN7O3Pureza:97.35% - 99.11%Cor e Forma:SolidPeso molecular:499.5Ref: TM-T2302
1mg38,00€2mg50,00€5mg84,00€1mL*10mM (DMSO)88,00€10mg119,00€25mg222,00€50mg369,00€100mg537,00€500mg1.161,00€Ibrutinib
CAS:Ibrutinib (PCI-32765) is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.Fórmula:C25H24N6O2Pureza:98% - 99.95%Cor e Forma:White SolidPeso molecular:440.50(Rac)-IBT6A
CAS:(Rac)-IBT6A is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib and can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.Fórmula:C22H22N6OPureza:99.24%Cor e Forma:SolidPeso molecular:386.45Ref: TM-T10626
1mg44,00€2mg57,00€1mL*10mM (DMSO)92,00€5mg93,00€10mg120,00€25mg215,00€50mg313,00€100mg439,00€200mg628,00€Avitinib
CAS:Avitinib (AC0010), also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor,Fórmula:C26H26FN7O2Pureza:99.81% - >99.99%Cor e Forma:White SolidPeso molecular:487.53CGI-1746
CAS:CGI1746 is a potent and highly selective small-molecule Btk inhibitor with IC50 of 1.9 nM.Fórmula:C34H37N5O4Pureza:97.69% - 97.88%Cor e Forma:White SolidPeso molecular:579.69RN486
CAS:RN486 is an effective and specific BTK inhibitor (IC50: 4 nM).Fórmula:C35H35FN6O3Pureza:99.38%Cor e Forma:SolidPeso molecular:606.69Branebrutinib
CAS:Branebrutinib (BMS986195) is a potent, covalent inhibitor of Bruton's tyrosine kinase (BTK), >5,000-fold selective over all kinases outside of the Tec family.Fórmula:C20H23FN4O2Pureza:95.86% - 99.31%Cor e Forma:SolidPeso molecular:370.42BIIB068
CAS:BIIB068 is an selective, reversible and orally active BTK inhibitor (IC50 = 1 nM, Kd = 0.3 nM). BIIB068 is 400 times more selective for BTK than other kinases.Fórmula:C23H29N7O2Pureza:97.98%Cor e Forma:White SolidPeso molecular:435.52Ref: TM-T9192
1mg46,00€5mg90,00€1mL*10mM (DMSO)100,00€10mg152,00€25mg264,00€50mg398,00€100mg532,00€200mg705,00€TL-895
CAS:TL-895 is a potent, selective ATP-competitive BTK inhibitor (IC50 = 1.5 nM, Ki = 11.9 nM).Fórmula:C25H26FN5O2Pureza:99.96%Cor e Forma:SolidPeso molecular:447.5Ref: TM-T9705
2mg39,00€5mg60,00€1mL*10mM (DMSO)60,00€10mg87,00€25mg172,00€50mg266,00€100mg391,00€200mg555,00€ONO-4059 analog
CAS:ONO-4059 analog (ONO-WG-307)ue is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.Fórmula:C25H24N6O3Pureza:99.93%Cor e Forma:SolidPeso molecular:456.5Ref: TM-T6921
1mg43,00€2mg56,00€1mL*10mM (DMSO)90,00€5mg93,00€10mg137,00€25mg264,00€50mg439,00€100mg627,00€BTK Protein, Human, Recombinant (His)
Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling.Pureza:90%Cor e Forma:Lyophilized PowderPeso molecular:78.3 kDa (predicted)Ibrutinib-D5
CAS:Ibrutinib D5 is a deuterium-labeled Ibrutinib. Ibrutinib is an irreversible Btk inhibitor.Fórmula:C25H24N6O2Pureza:98%Cor e Forma:SolidPeso molecular:445.53Dihydrodiol-Ibrutinib
CAS:PCI 45227 is an active metabolite of the Bruton's tyrosine kinase inhibitor ibrutinib .1PCI 45227 is formed from ibrutinib by the cytochrome P450 (CYP) isoform CYP3A. 1.Veeraraghavan, S., Viswanadha, S., Thappali, S., et al.Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: Application to a pharmacokinetic studyJ. Pharm. Biomed. Anal.107151-158(2015)Fórmula:C25H26N6O4Cor e Forma:SolidPeso molecular:474.521CP-547632
CAS:CP-547632 is an oral ATP-competitive inhibitor of VEGFR-2/FGF kinase with IC50s of 11/9 nM, highly selective, has antitumor activity.Fórmula:C20H24BrF2N5O3SPureza:99.14%Cor e Forma:SolidPeso molecular:532.4DPPY
CAS:DPPY inhibits EGFR, BTK, JAK3 (IC50<10 nM), curbs B-cell lymphoma growth, and may be studied for IPF treatment.Fórmula:C25H26ClN7O3Cor e Forma:SolidPeso molecular:507.97XMU-MP-2
CAS:XMU-MP-2 is a potent and selective protease inhibitor with anticancer activity that inhibits the growth of oncogenic BRK-driven tumors in a mouse xenograftFórmula:C32H33F3N8O2Pureza:99.97%Cor e Forma:White SolidPeso molecular:618.65JAK3/BTK-IN-2
CAS:JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor.Fórmula:C25H32N8O2Pureza:99.64% - 99.87%Cor e Forma:White SolidPeso molecular:476.57VA5 TG2 inhibitor
CAS:VA5 inhibits transamidase and GTP-binding by locking protein in an open state, disabling GTPase.Fórmula:C31H34N4O8Pureza:98%Cor e Forma:SolidPeso molecular:590.62CGI560
CAS:CGI560 is a potent BTK inhibitor with IC50 = 400 nM for BTK.Fórmula:C29H27N5OCor e Forma:SolidPeso molecular:461.56HZ-A-005
CAS:HZ-A-005 is a selective, potent, covalent inhibitor of Bruton's tyrosine kinase (BTK). HZ-A-005 significantly inhibits tumour growth in a xenograft mouse model.Fórmula:C25H23ClN6O2Cor e Forma:SolidPeso molecular:474.94GDC-0834 S-enantiomer
CAS:GDC-0834, the S-enantiomer, is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK).Fórmula:C33H36N6O3SPureza:98%Cor e Forma:SolidPeso molecular:596.74BLK-IN-2
CAS:BLK-IN-2为一种高效、选择性且不可逆的B-淋巴酪氨酸激酶(BLK)抑制剂，具有5.9 nM的IC50值。该化合物亦能抑制BTK，其IC50值为202.0 nM。BLK-IN-2在多种淋巴瘤细胞中展现出显著的抗增殖作用。Fórmula:C39H41N9O3Cor e Forma:SolidPeso molecular:683.8GDC-0834 Racemate
CAS:GDC-0834 Racemate is the racemate form of GDC-0834, which is an effective and selective BTK inhibitorFórmula:C33H36N6O3SCor e Forma:SolidPeso molecular:596.74JAK3/BTK-IN-5
CAS:JAK3/BTK-IN-5 is a potent dual inhibitor targeting JAK3 and BTK with synergistic effects, valuable for related autoimmune disease research.Fórmula:C19H22ClN7O2Cor e Forma:SolidPeso molecular:415.88Ibrutinib-MPEA
CAS:Ibrutinib-MPEA is ibrutinib derivative. Ibrutinib is a covalent and irreversible BTK inhibitor that has been used to treat hematological malignancies.Fórmula:C32H39N9O2Cor e Forma:SolidPeso molecular:581.71SJF620
CAS:SJF620 is a potent degrader of PROTAC BTK(DC50 : 7.9 nM).Fórmula:C41H44N8O7Pureza:98%Cor e Forma:SolidPeso molecular:760.84BTK inhibitor 10
CAS:BTK inhibitor 10, an oral drug from patent WO2018145525, may treat rheumatoid arthritis.Fórmula:C25H23N5O3Pureza:98%Cor e Forma:SolidPeso molecular:441.48EGFR-IN-40
CAS:EGFR-IN-40 (compound 3z) is a potent inhibitor of BTK (IC50: 1.2 nM), EGFR (IC50: 5.3 nM) and ITK (IC50: 46.1 nM).Fórmula:C23H20N6O3Cor e Forma:SolidPeso molecular:428.44
